兔玻璃体腔注射Dn-MyD88腺病毒载体观察对PVR形态学的影响

目的:重组Dn-MyD88(Dominant negative myeloid differentiation factor88,Dn-MyD88)腺病毒载体观察对增殖性玻璃体视网膜病变形态学的影响。方法:向兔眼内注射富含血小板浓度为5×107～10×107/ml的血浆制作PVR模型,并对MyD88介导的NF-κB信号通路进行了分析。向兔眼玻璃体腔内转染腺病毒携带的无功能MyD88,运用眼B超,眼底照相等方法,于1,7,14,21,28天观察PVR形态学变化。结果:在增殖性玻璃体视网膜病变中通过转染腺病毒携带的无功能MyD88,与对照组相比发现增殖膜有减少趋势。结论:在兔眼PVR模型中转染腺病毒携带的无功能MyD88可抑制PVR的发生发展,可为临床PVR的治疗提供有益的参考和借鉴。     

兔眼增殖性玻璃体视网膜病变模型的建立

目的探讨兔眼增殖性玻璃体视网膜病变模型的建立方法。方法①体外培养兔眼视网膜色素上皮细胞;②兔眼3组,每组6只,分别在玻璃体内注射0.1 mL的生理盐水、1×106细胞及2×106细胞,在不同时间段进行裂隙灯显微镜、间接检眼镜、眼底照像和B超检查,观察成模情况。结果注射后28 d,生理盐水组成模0眼;1×106细胞组成模5眼,其中Ⅰ级眼1只,Ⅱ级眼3只,Ⅲ级眼1只;2×106细胞组成模6眼,其中Ⅱ级眼2只,Ⅲ级眼4只。结论兔眼玻璃体内注射2×106同种视网膜色素上皮细胞建立增殖性玻璃体视网膜病变模型,符合病变发展规律,而且稳定可靠,成模较快,简单易行。     

HIV-1 gagpol重组腺病毒疫苗的构建及其免疫原性的研究

目的：构建HIV-1重组腺病毒疫苗并初步鉴定其免疫原性。方法：用Adeno-XExpressionSystem试剂盒将HIV—lgagpol基因片段插入到腺病毒载体上,通过脂质体介导将获得的重组腺病毒质粒Adeno—X-gagpol转染至293细胞,使之自主包装成有感染活性的重组腺病毒tad—gagpol,用western-blotting法鉴定其表达情况;用CsCl密度梯度离心法纯化该重组腺病毒,以5×10^8 pfu／mL的滴度lmL单次免疫小鼠,15天后测小鼠体液免疫效果。结果：克隆序列与设计相符,重组腺病毒疫苗能稳定表达gag—pol蛋白,体液免疫中检测出抗p55和p24的特异性抗体。结论：HIV—lgagpol重组腺病毒构建成功,具有一定的体液免疫原性。     

MyD88aa155-171功能区缺失对免疫相关细胞共刺激分子和细胞因子表达的影响

利用重组PCR的方法,克隆并构建MyD88和MyD88aa155-171功能区缺失（MyD88?155-171）载体,转染免疫相关细胞并筛选获得稳定细胞系。报告基因实验结果显示MyD88?155-171功能区缺失能够抑制转录因子NF-κB和AP-1的活性,在不同Toll样受体（TLR）配体刺激后,转染MyD88?155-171的细胞表面分子的表达低于MyD88正常表达的细胞,并且抑制表面分子CD86和B7H1在TLR配体刺激后的上调。同时,多细胞因子分析系统的检测结果表明,给予TLR配体刺激之后,MyD88-/-树突细胞表达低水平的细胞因子,转染MyD88可以使细胞因子表达明显增加,而仅表达MyD88?155-171可以明显影响IL-12,IFN- 的表达。以上结果表明MyD88功能区缺失影响免疫相关细胞表面分子和细胞因子的表达及Toll 样受体信号的传递,其在细胞内信号系统的具体作用机制还需进一步证实。     

增生性玻璃体视网膜病变动物模型的改进和评价

增生性玻璃体视网膜病变是导致视网膜脱离手术失败的主要原因,建立动物模型能更好的研究其发病机理,从而进行防治。本文就PVR动物模型的所用动物、模型的建立方法以及评价和分级进行综述。     

玻璃体视网膜手术治疗先天性视网膜劈裂及其并发症的临床疗效

目的:评价玻璃体视网膜手术治疗先天性视网膜劈裂及其并发症的临床疗效。方法:选择2009年1月-2012年1月于我院进行玻璃体视网膜手术的先天性视网膜劈裂患者30例(42只眼),患者均接受了闭合式睫状体经扁平部三切口入路保留晶状体的玻璃体切割手术,并分析其术前及术后情况。结果:先天性视网膜劈裂患者中发生孔源性视网膜脱离19眼,牵拉性视网膜脱离8眼,玻璃体积血10眼,同时伴有视网膜脱离和玻璃体积血有5眼;在末次随访时视力提高者有36只眼,占85.71%,无提高者有6只眼,占14.29%;术前平均视力为(0.15±0.09),末次随访时平均视力提高至(0.31±0.16),两者平均视力差异具有统计学意义(t=5.649,P0.001);42只眼视网膜解剖结构复位良好,视网膜平伏;OCT检查结果显示,末次随访时黄斑劈裂平均面积(0.22±0.18)mm2,与术前黄斑劈裂平均面积(1.07±0.52)mm2比较,差异有统计学意义(t=10.011,P0.001),黄斑微囊样改变有改善;随访期间5只眼出现并发症,占11.90%,其中2眼术后发生PVR且伴牵拉性视网膜脱离,2只眼发生白内障,1只眼出现玻璃体积血,术后视网膜解剖均复位良好。结论:玻璃体视网膜手术可以帮助患者进行视网膜解剖复位及提高其先天性视网膜劈裂患者视功能,具有良好的临床疗效。     

玻璃体腔注药联合微创玻璃体切除治疗糖尿病视网膜病变的临床疗效研究

目的:探讨玻璃体腔注药联合微创玻璃体切除治疗糖尿病视网膜病变的临床疗效。方法:选择2014年1月至2016年1月在我院确诊并治疗的增生性糖尿病视网膜病变患者80例,共83只患眼,随机分为A、B两组。A组共42例患眼,接受25 G玻璃体微创手术;B组共41例患眼,在A组治疗的基础上给予玻璃体腔注射康柏西普。比较两组患者的手术情况、治疗前后最佳视力的矫正(Best-corrected visual acuity,BCVA)情况、视网膜厚度以及术后1个月不良反应的发生情况。结果:B组患者的手术时间较A组显著缩短(P0.05),且术中使用电凝的患眼、术中出血以及术中发生医源性裂隙的患眼比例显著低于A组(P0.05),新生血管消失的患眼比例显著高于A组(P0.05)。B组患者术后1个月和3个月的BVCA显著高于A组(P0.05),且术后视网膜的厚度显著薄于A组(P0.05),术后发生玻璃体积血和前方出血的患眼比例显著低于A组(P0.05)。结论:玻璃体腔注射康柏西普联合25G玻璃体微创切除术治疗增生性糖尿病视网膜病变的临床疗效显著,有利于患者术后视力以及视网膜恢复。     

康柏西普预防严重后巩膜裂伤玻璃体切除术后增生性玻璃体视网膜病变的临床疗效

摘要 目的：探讨玻璃体腔注射康柏西普对于严重后巩膜裂伤患者玻璃体切除术后增生性玻璃体视网膜病变发生的预防效果。方法：选取从2018年9月至2020年9月我院收治的40例（40眼）严重后巩膜裂伤患者进行研究,随机分为对照组20眼（行常规巩膜裂伤缝合术及经睫状体平坦部玻璃体切除术）和观察组20眼（行巩膜裂伤缝合术及经睫状体平坦部玻璃体切除术的同时联合玻璃体腔注射康柏西普治疗）。比较两组患者术前及术后的视力、眼压,以及术后增生性玻璃体视网膜病变的发生率、视网膜再脱离的发生率。结果：对照组及观察组术后的最佳矫正视力较术前均提高、术后眼压均正常,观察组术后的增生性玻璃体视网膜病变发生率（15.0 %）明显低于对照组（45.0 %, P<0.05）,观察组术后视网膜脱离复发率（5.0 %）低于对照组（30.0 %, P>0.05）。结论：严重后巩膜裂伤患者玻璃体切除术联合玻璃体注射康柏西普治疗能够有效降低增生性玻璃体视网膜病变的发生率和术后视网膜脱离的复发率,还可以改善患者的视力预后。     

FOX03a过表达对内皮祖细胞周期相关蛋白的调控

目的：观察FOXO3a（forkhead box O3a）的活性改变对内皮祖细胞（endothelial progenitor cells,EPCs）增殖和细胞周期相关蛋白表达的影响。方法：将携带突变激活FOXO3a基因的腺病毒载体Ad-TM（triple mutant）-FOXO3a和阴性对照腺病毒载体Ad-GFP体外感染人脐血来源的EPCs。观察EPCs形态学改变,CCK-8分析转染后EPCs增殖情况,Western blot检测FOXO3a蛋白、细胞周期相关蛋白p27^kip1以及CDK2的表达水平。结果：构建了的2种腺病毒相关载体被成功转染。形态学改变方面,Ad-TM—FOXO3a组EPCs细胞生长缓慢,集落不明显;Westem blot和CCK-8结果显示,Ad-TM—FOXO3a转染组与阴性对照组相比,EPCs增殖被抑制,FOXO3a与p27^kip1蛋白过表达,CDK2表达下调。结论：FOXO3a可能通过上调p27kip1蛋白表达,下调CDK2表达,以抑制EPCs增殖。     

Tbx18 能使兔脂肪干细胞向心肌样细胞分化

目的:研究Tbx18是否能成功转染脂肪干细胞并使脂肪干细胞向心肌细胞分化。方法:分离培养来源于日本大耳兔腹股沟部脂肪的兔脂肪干细胞,用搭载有Tbx18的腺病毒载体转染脂肪干细胞,诱导分化后检测向心肌细胞的分化情况,同时将转染了含GFP的腺病毒组与未转染组作为对照。采用用流式细胞仪检测转染效率,采用免疫荧光法检测平滑肌肌动蛋白α-SMA,采用实时定量PCR法检测兔肌钙蛋白TNNT2的表达。结果:转染后荧光显微镜下可观察到荧光表达,且持续时间较长。流式细胞仪检测转染效率为70%左右;诱导分化后,脂肪干细胞内出现了α-SMA和TNNT2的表达。结论:Tbx18可成功转染入脂肪干细胞,且能在细胞内稳定表达;Tbx18可诱导脂肪干细胞向心肌样细胞分化。     

Differential role of TLR- and RLR-signaling in the immune responses to influenza A virus infection and vaccination

The innate immune system recognizes influenza A virus via TLR 7 or retinoic acid-inducible gene I in a cell-type specific manner in vitro, however, physiological function(s) of the MyD88- or interferon-beta promoter stimulator 1 (IPS-1)-dependent signaling pathways in antiviral responses in vivo remain unclear. In this study, we show that although either MyD88- or IPS-1-signaling pathway was sufficient to control initial antiviral responses to intranasal influenza A virus infection, mice lacking both pathways failed to show antiviral responses, resulting in increased viral load in the lung. By contrast, induction of B cells or CD4 T cells specific to the dominant hemagglutinin or nuclear protein Ags respectively, was strictly dependent on MyD88 signaling, but not IPS-1 signaling, whereas induction of nuclear protein Ag-specific CD8 T cells was not impaired in the absence of either MyD88 or IPS-1. Moreover, vaccination of TLR7- and MyD88-deficient mice with inactivated virus failed to confer protection against a lethal live virus challenge. These results strongly suggest that either the MyD88 or IPS-1 signaling pathway is sufficient for initial antiviral responses, whereas the protective adaptive immune responses to influenza A virus are governed by the TLR7-MyD88 pathway.     

Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling

MyD88 is a Toll/IL-1 receptor (TIR) domain-containing adapter common to signaling pathways via Toll-like receptor (TLR) family. However, accumulating evidence demonstrates the existence of a MyD88-independent pathway, which may explain unique biological responses of individual TLRs, particularly TLR3 and TLR4. TIR domain-containing adapter protein (TIRAP)/MyD88 adapter-like, a second adapter harboring the TIR domain, is essential for MyD88-dependent TLR2 and TLR4 signaling pathways, but not for MyD88-independent pathways. Here, we identified a novel TIR domain-containing molecule, named TIR domain-containing adapter inducing IFN-beta (TRIF). As is the case in MyD88 and TIRAP, overexpression of TRIF activated the NF-kappaB-dependent promoter. A dominant-negative form of TRIF inhibited TLR2-, TLR4-, and TLR7-dependent NF-kappaB activation. Furthermore, TRIF, but neither MyD88 nor TIRAP, activated the IFN-beta promoter. Dominant-negative TRIF inhibited TLR3-dependent activation of both the NF-kappaB-dependent and IFN-beta promoters. TRIF associated with TLR3 and IFN regulatory factor 3. These findings suggest that TRIF is involved in the TLR signaling, particularly in the MyD88-independent pathway.     

Signaling flux redistribution at toll-like receptor pathway junctions

Various receptors on cell surface recognize specific extracellular molecules and trigger signal transduction altering gene expression in the nucleus. Gain or loss-of-function mutations of one molecule have shown to affect alternative signaling pathways with a poorly understood mechanism. In Toll-like receptor (TLR) 4 signaling, which branches into MyD88- and TRAM-dependent pathways upon lipopolysaccharide (LPS) stimulation, we investigated the gain or loss-of-function mutations of MyD88. We predict, using a computational model built on the perturbation-response approach and the law of mass conservation, that removal and addition of MyD88 in TLR4 activation, enhances and impairs, respectively, the alternative TRAM-dependent pathway through signaling flux redistribution (SFR) at pathway branches. To verify SFR, we treated MyD88-deficient macrophages with LPS and observed enhancement of TRAM-dependent pathway based on increased IRF3 phosphorylation and induction of Cxcl10 and Ifit2. Furthermore, increasing the amount of MyD88 in cultured cells showed decreased TRAM binding to TLR4. Investigating another TLR4 pathway junction, from TRIF to TRAF6, RIP1 and TBK1, the removal of MyD88-dependent TRAF6 increased expression of TRAM-dependent Cxcl10 and Ifit2. Thus, we demonstrate that SFR is a novel mechanism for enhanced activation of alternative pathways when molecules at pathway junctions are removed. Our data suggest that SFR may enlighten hitherto unexplainable intracellular signaling alterations in genetic diseases where gain or loss-of-function mutations are observed.     

MyD88 plays an essential role in inducing B cells capable of differentiating into antibody-secreting cells after vaccination

We investigated the roles of MyD88, an innate adaptor signaling molecule, in inducing protective humoral immunity after vaccination with influenza virus-like particles (VLPs). MyD88 knockout C57BL/6 mice (MyD88(-/-) mice) vaccinated with influenza VLPs showed significant defects in inducing IgG2a/c isotype antibodies and in generating splenic recall memory B cell responses and antibody-secreting plasma cells in the bone marrow. The protective efficacy of influenza VLP vaccination was lower in MyD88(-/-) mice than in the wild-type mice. Our findings indicate that MyD88-mediated innate signaling pathways are important for effectively inducing primary and boost immune responses, T helper type 1 isotype-switched antibodies, and gamma interferon (IFN-γ)-secreting T cell responses. In particular, the results in this study demonstrated for the first time that MyD88-mediated immune activation is likely an essential pathway for effective generation of long-lived antibody-secreting plasma cells and highly protective immunity after vaccination with influenza VLPs. This study provides insight into mechanisms by which recombinant viral vaccines induce protective immunity via the MyD88-mediated innate immune signaling pathway.     

Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes.

Bacterial lipopolysaccharide (LPS) triggers innate immune responses through Toll-like receptor (TLR) 4, a member of the TLR family that participates in pathogen recognition. TLRs recruit a cytoplasmic protein, MyD88, upon pathogen recognition, mediating its function for immune responses. Two major pathways for LPS have been suggested in recent studies, which are referred to as MyD88-dependent and -independent pathways. We report in this study the characterization of the MyD88-independent pathway via TLR4. MyD88-deficient cells failed to produce inflammatory cytokines in response to LPS, whereas they responded to LPS by activating IFN-regulatory factor 3 as well as inducing the genes containing IFN-stimulated regulatory elements such as IP-10. In contrast, a lipopeptide that activates TLR2 had no ability to activate IFN-regulatory factor 3. The MyD88-independent pathway was also activated in cells lacking both MyD88 and TNFR-associated factor 6. Thus, TLR4 signaling is composed of at least two distinct pathways, a MyD88-dependent pathway that is critical to the induction of inflammatory cytokines and a MyD88/TNFR-associated factor 6-independent pathway that regulates induction of IP-10.     

Mycobacterial infection in MyD88-deficient mice

MyD88 is an adaptor protein that plays a major role in TLR/IL-1 receptor family signaling. To understand the role of MyD88 in the development of murine tuberculosis in vivo, MyD88 knockout (KO) mice aerially were infected with Mycobacterium tuberculosis. Infected MyD88 mice were not highly susceptible to M. tuberculosis infection, but they developed granulomatous pulmonary lesions with neutrophil infiltration which were larger than those in wild-type (WT) mice (P < 0.01). The pulmonary tissue levels of mRNA for iNOS and IL-18 were slightly lower, but levels of mRNA for IL-1 beta, IL-2, IL-4, IL-6, IL-10, IFN-gamma, and TGF-beta were higher in MyD88 KO mice. IFN-gamma, TNF-alpha, IL-1 beta, and IL-12 also were high in the sera of MyD88 KO mice. There were no statistically significant differences in the expression of TNF-alpha, IL-12, and ICAM-1 mRNA between MyD88 KO and WT mice. Thus, MyD88 deficiency did not influence the development of murine tuberculosis. NF-kappa B activity was similar in the alveolar macrophages from the lung tissues of MyD88 KO and WT mice. Also, there may be a TLR2-specific, MyD88-independent IL-1 receptor/TLR-mediated pathway to activate NF-kappa B in the host defense against mycobacterial infection.     

Role for MyD88 signaling in murine gammaherpesvirus 68 latency

Toll-like receptors (TLRs) are known predominantly for their role in activating the innate immune response. Recently, TLR signaling via MyD88 has been reported to play an important function in development of a B-cell response. Since B cells are a major latency reservoir for murine gammaherpesvirus 68 (MHV68), we investigated the role of TLR signaling in the establishment and maintenance of MHV68 latency in vivo. Mice deficient in MyD88 (MyD88(-/-)) or TLR3 (TLR3(-/-)) were infected with MHV68. Analysis of splenocytes recovered at day 16 postinfection from MyD88(-/-) mice compared to those from wild-type control mice revealed a lower frequency of (i) activated B cells, (ii) germinal-center B cells, and (iii) class-switched B cells. Accompanying this substantial defect in the B-cell response was an approximately 10-fold decrease in the establishment of splenic latency. In contrast, no defect in viral latency was observed in TLR3(-/-) mice. Analysis of MHV68-specific antibody responses also demonstrated a substantial decrease in the kinetics of the response in MyD88(-/-) mice. Analysis of wild-type x MyD88(-/-) mixed-bone-marrow chimeric mice demonstrated that there is a selective failure of MyD88(-/-) B cells to participate in germinal-center reactions as well as to become activated and undergo class switching. In addition, while MHV68 established latency efficiently in the MyD88-sufficient B cells, there was again a ca. 10-fold reduction in the frequency of MyD88(-/-) B cells harboring latent MHV68. This phenotype indicates that MyD88 is important for the establishment of MHV68 latency and is directly related to the role of MyD88 in the generation of a B-cell response. Furthermore, the generation of a B-cell response to MHV68 was intrinsic to B cells and was independent of the interleukin-1 receptor, a cytokine receptor that also signals through MyD88. These data provide evidence for a unique role for MyD88 in the establishment of MHV68 latency.     

Multiple innate immune pathways contribute to the immunogenicity of recombinant adenovirus vaccine vectors

The innate immune pathways that contribute to the potent immunogenicity of recombinant adenovirus (rAd) vaccine vectors remain largely undefined. Previous studies assessing innate immunity triggered by vaccine vectors have largely focused on in vitro studies involving antigen-presenting cells and on early in vivo inflammatory responses. Here, we systematically explore the Toll-like receptor (TLR) signaling requirements for the generation of cellular immune responses by intramuscular immunization with common and alternative serotype rAd vectors in mice. Antigen-specific CD8(+) T-lymphocyte responses elicited by these rAd vectors were significantly diminished in MyD88(-/-) mice but not in TRIF(-/-) or TLR3(-/-) mice, suggesting the importance of MyD88-dependent TLR signaling. However, the absence of each individual TLR resulted in minimal to no effect on vaccine-elicited cellular immune responses. Moreover, responses were not diminished in IL-1R(-/-) or IL-18R(-/-) mice. These data suggest that rAd vectors engage multiple MyD88-dependent signaling pathways, none of which are individually critical; rather, they are integrated to contribute to the potent immunogenicity of rAd vectors. Stimulation of multiple innate immune mechanisms may prove a generalizable property of potent vaccines, and this strategy could be harnessed in the development of next-generation vaccine vectors and adjuvants.